03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the midterm...
21:00 , Jun 7, 2018 |  BC Extra  |  Company News

BrainStorm considering right to try for ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury. He also discussed the company’s plans on...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
21:47 , Nov 30, 2017 |  BC Innovations  |  Targets & Mechanisms

All-purpose HSCs

While most eyes are on hematopoietic stem cells for their ability to treat blood cancers, a UCSD group has built a body of work showing the immune cell precursors can treat diseases with no relation...
01:31 , Sep 2, 2017 |  BioCentury  |  Strategy

Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
01:48 , Dec 22, 2016 |  BC Innovations  |  Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
00:14 , Nov 22, 2016 |  BC Innovations  |  Strategy

China’s dysfunctional patent flood

Although labs throughout China are turning out high profile biomedical studies at an impressive clip, the country still lags in its ability to commercialize valuable discoveries. A new study argues this is because bad patents...